Edition:
United Kingdom

PAION AG (PA8G.DE)

PA8G.DE on Xetra

2.48EUR
11:36am GMT
Change (% chg)

€0.00 (+0.04%)
Prev Close
€2.48
Open
€2.50
Day's High
€2.51
Day's Low
€2.47
Volume
17,590
Avg. Vol
153,187
52-wk High
€3.53
52-wk Low
€2.15

Summary

Name Age Since Current Position

Joerg Spiekerkoetter

59 2010 Chairman of the Supervisory Board

Wolfgang Soehngen

Chairman of the Management Board, Chief Executive Officer

Karin Dorrepaal

56 2012 Deputy Chairman of the Supervisory Board

Abdelghani Omari

2014 Chief Financial Officer, Member of the Management Board

Irina Antonijevic

2017 Member of the Supervisory Board

John Dawson

56 2014 Member of the Supervisory Board

Chris Tanner

2017 Member of the Supervisory Board

Ralf Penner

Vice President Investor Relations / Public Relations

Biographies

Name Description

Joerg Spiekerkoetter

Dr. Joerg Spiekerkoetter has been Chairman of the Supervisory Board of Paion AG since May 19, 2010. He was previously Vice Chairman of the Supervisory Board of Paion AG from August 6, 2008. Prior to that, he served as Member of the Supervisory Board at the Company from June 20, 2007. He has many years of experience in the pharmaceutical industry where he has held executive positions in the areas of finance, law and human resources. Until May 2007, he was the Chief Financial Officer of Organon BioSciences NV, Oss, the Netherlands. He left after the acquisition of the company by the US pharmaceutical company Schering-Plough. Until September 2006, he was Chief Financial Officer at Schering AG in Berlin, Germany, and before that, he was Head of the Legal Department at Hoechst Schering AgrEvo GmbH in Berlin, Germany. Dr. Spiekerkoetter studied at Universitaet Bielefeld, University de Lausanne and Universitaet Freiburg, and holds a Ph.D. degree in law. In November 2007, he became Chief Financial Officer of Conergy AG, Hamburg, Germany.

Wolfgang Soehngen

Dr. Wolfgang Soehngen serves as Chairman of the Management Board and Chief Executive Officer of Paion AG. He initially worked as pharmaceutical representative for Pfizer Pharma GmbH. He received a Ph.D. degree in 1985, after having graduated from Rhenisch-Westfaelische Technische Hochschule Aachen (RWTH Aachen Medical School) in 1984. After two years as an intern in internal medicine at a teaching hospital, he took on a post doc position in cardiovascular pharmacology (1986-1987) at the University of Michigan, Ann Arbor. Subsequently, he worked for Gruenenthal GmbH, where his tasks included clinical development, project management, corporate development and strategic planning. In 1996, he received a Diploma in Pharmaceutical Medicine (DGPharMed). In 1997, he founded his own consulting firm Virtueality, which specialized in healthcare and clinical development. He also obtained a Master of Business Communication in 1999. Together with Dr. Mariola Soehngen, he founded Paion AG and Paion Deutschland GmbH. He currently serves also as a Managing Director of Paion Deutschland GmbH.

Karin Dorrepaal

Dr. Karin Louise Dorrepaal has been Deputy Chairman of the Supervisory Board at PAION AG since October 29, 2012. She is Chairman of the Human Resources & Nomination Committee at the Company. Between 2004 and 2006, Dr. Dorrepaal was a member of the Management Board of Schering AG in Berlin. From 1990 to 2004 she worked as management consultant at Booz Allen & Hamilton in Amsterdam and New York. From 1985 until 1988 she was a Ph.D. Research Fellow at The Netherlands Cancer Institute in Amsterdam. She has been on the Supervisory Board of Gerresheimer AG and Julius Clinical Research BV, among others.

Abdelghani Omari

Mr. Abdelghani Omari has been Chief Financial Officer and Member of the Management Board of PAION AG since September 1, 2014. He has been with the Company as Vice President Finance since October 2008. Mr. Omari has worked on the restructuring process and the repositioning of PAION AG in the last years and was responsible and involved in various capital market transactions and licensing agreements as Vice President Finance. Prior to joining the company, he held various positions at KPMG, Cologne in auditing and advisory. He studied at the University of Aachen and has a Diploma in Business Administration.

Irina Antonijevic

Dr. Irina Antonijevic has been Member of the Supervisory Board at PAION AG since May 17, 2017. She is Chairman of the Research & Development Committee at the Company. She joined vasopharm GmbH in 2016 as Chief Medical Officer. She has more than 16 years of drug development experience in different pharmaceutical organizations, with a focus on neuropsychiatric and rare diseases. In her last role at Sanofi Genzyme in Cambridge, she oversaw multiple innovative clinical programs as Global Head Early Development Neurology and Ophthalmology. She completed her medical studies at the Technical University of Munich (1991), received her MD from the Max Planck Institute in Munich (1992) and her Ph.D. from the University of Edinburgh (1995). She completed her residency at the Max Planck Institute of Psychiatry in Munich and received her Venia Legendi from the Charite, Berlin, in 2004. Dr. Antonijevic has been a regular reviewer for the German Ministry of Research (BMBF) since 2006.

John Dawson

Mr. John Dawson has been Member of the Supervisory Board at Paion AG since May 21, 2014. He is Chairman of the Audit Committee at the Company. He is Chief Executive Officer of Oxford BioMedica. From 1996 to 2007 he held senior management positions in the European operations of Cephalon Inc., including from 2005, a management board position as Chief Financial Officer and Head of Business Development Europe. Between 1991 and 1996 he was Director of Finance and Administration of Serono Laboratories (UK) Limited.

Chris Tanner

Dr. Chris Tanner has been Member of the Supervisory Board at PAION AG since May 17, 2017. He was a member of the Executive Board since 2005 and has been a member of the Supervisory Board of Cosmo Pharmaceuticals N.V. since 2006 for which he conducted the IPO as Chief Financial Officer and Head of Investor Relations. In 2015, Cosmo span off the daughter Cassiopea SpA where he also acts as Chief Financial Officer and Head of Investor Relations. Moreover, he is a member of the board of directors or advisory board of listed DKSH AG, Private Equity Holding AG and the private medtec companies Qvanteq AG and Joimax GmbH. From 1998 to 2001, he was a partner of Dr. Ernst Mueller-Moehl and co-founder of the 20 Minutes group of newspapers and founded A&A Active Investor, a SIX-listed investment company. From 1992 to 1998, he was the Head of Corporate Finance & Capital Markets at UBS in Zurich, and from 1976 to 1991 he had various functions in the Corporate Banking Department at UBS in Zurich, Madrid and Los Angeles. Dr. Tanner has a Ph.D. in economics and a diploma as economist from the University of St. Gallen.

Ralf Penner

Basic Compensation

Name Fiscal Year Total

Joerg Spiekerkoetter

55,000

Wolfgang Soehngen

555,081

Karin Dorrepaal

41,250

Abdelghani Omari

306,737

Irina Antonijevic

--

John Dawson

26,000

Chris Tanner

--

Ralf Penner

--
As Of  31 Dec 2016